Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy

Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy

Angiotensin‐converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure‐independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of ACEi on anti‐fibrotic biomarkers in African Americ...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2021-05, Vol.23 (5), p.1008-1016
Main Authors: Romero, Cesar, Mathew, Shobi, Wasinski, Benjamin, Reed, Brian, Brody, Aaron, Dawood, Rachelle, Twiner, Michael J., McNaughton, Candace D., Fridman, Rafael, Flack, John M., Carretero, Oscar A., Levy, Phillip D.
Format: Article
Language:eng
Subjects:
ACE inhibitors
Ac‐SDKP
Adult
African American
African Americans
Alfacalcidol
Analysis
Angiotensin
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive drugs
Antihypertensives
Anti‐fibrotic Biomarkers
Biological markers
Biomarkers
Blood pressure
Calcifediol
Cardiovascular disease
Cocaine
Collagen
Enzymes
Fibroblasts
Heart attacks
Heart enlargement
Humans
Hypertension
Hypertension - drug therapy
Hypertrophy, Left Ventricular - drug therapy
left ventricular hypertrophy
Mental disorders
Middle Aged
MMP‐1
Original Paper
Patients
Peptides
Proline
Vitamin D
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiotensin‐converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure‐independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of ACEi on anti‐fibrotic biomarkers in African American hypertensive patients with left ventricular hypertrophy (LVH). We conducted a post hoc analysis of a randomized controlled trial in which hypertensive African American patients with LVH and vitamin D deficiency were randomized to receive intensive antihypertensive therapy plus vitamin D supplementation or placebo. We selected patients who had detectable lisinopril (lisinopril group) in plasma using liquid‐chromatography/mass spectrometry analysis and compared them to subjects who did not (comparison group) at the one‐year follow‐up. The pro‐fibrotic marker type 1 procollagen C‐terminal propeptide (PICP) and the anti‐fibrotic markers matrix metalloproteinase‐1 (MMP‐1), tissue inhibitor of metalloproteinases 1 (TIMP‐1), telopeptide of collagen type I (CITP), and N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (Ac‐SDKP) peptide were measured. Sixty‐six patients were included, and the mean age was 46.2 ± 8 years. No difference was observed in the number and intensity of antihypertensive medications prescribed in each group. Patients with detectable lisinopril had lower blood pressure than those in the comparison group. The anti‐fibrotic markers Ac‐SDKP, MMP‐1, and MMP‐1/TIMP‐1 ratio were higher in patients with detectable ACEi (all p 
ISSN:1524-6175
1751-7176